Blue Earth Diagnostics Limited
Private Limited Company · Oxford
ActiveUnited KingdomIncorporated 2013Private Limited Company
Documents & history
Available account evidence and business events. This is not a complete filing history or document library.
Accounts to 2025-12-31
IXBRL · 316 source facts · 24 selected values
Not assessedlegacy record
Accounts to 2025-12-31
IXBRL · 316 source facts · 24 selected values
Not assessed
legacy record
- Reporting period
- 2025-01-01 to 2025-12-31
- Extraction status
- Legacy / not assessed
- Numeric facts
- 191
- Documents processed
- Not recorded
- XBRL standards validation
- Not assessed
- Filing-profile validation
- Not assessed
- Parser
- Legacy parser
- Taxonomy
- FRS-102-2025-01-01.xsd
- Currency
- GBP
- Source identifier
- Prod223_4259_08773116_20251231
- Source archive
- Accounts_Bulk_Data-2026-07-09.zip
Accounts to 2025-12-31
IXBRL · 316 source facts · 24 selected values
Validation findingsXBRL valid
Accounts to 2025-12-31
IXBRL · 316 source facts · 24 selected values
Validation findings
XBRL valid
- Reporting period
- 2025-01-01 to 2025-12-31
- Extraction status
- complete
- Numeric facts
- 191
- Documents processed
- 1
- XBRL standards validation
- valid
- Filing-profile validation
- invalid
- Parser
- arelle 2.44.4
- Taxonomy
- FRS-102-2025-01-01.xsd
- Currency
- GBP
- Source identifier
- Prod224_2607_08773116_20251231
- Source archive
- Accounts_Monthly_Data-July2026.zip
Extraction findings: filing rules invalid. These describe source processing, not an audit opinion on the company.
Accounts to 2024-12-31
IXBRL · 320 source facts · 28 selected values
Validation findingsXBRL valid
Accounts to 2024-12-31
IXBRL · 320 source facts · 28 selected values
Validation findings
XBRL valid
- Reporting period
- 2024-01-01 to 2024-12-31
- Extraction status
- complete
- Numeric facts
- 194
- Documents processed
- 1
- XBRL standards validation
- valid
- Filing-profile validation
- invalid
- Parser
- arelle 2.44.4
- Taxonomy
- FRS-102-2024-01-01.xsd
- Currency
- GBP
- Source identifier
- Prod224_2505_08773116_20241231
- Source archive
- Accounts_Monthly_Data-May2025.zip
Extraction findings: filing rules invalid. These describe source processing, not an audit opinion on the company.
Accounts to 2023-12-31
IXBRL · 315 source facts · 28 selected values
Not assessedlegacy record
Accounts to 2023-12-31
IXBRL · 315 source facts · 28 selected values
Not assessed
legacy record
- Reporting period
- 2023-01-01 to 2023-12-31
- Extraction status
- Legacy / not assessed
- Numeric facts
- 190
- Documents processed
- Not recorded
- XBRL standards validation
- Not assessed
- Filing-profile validation
- Not assessed
- Parser
- Legacy parser
- Taxonomy
- FRS-102-2023-01-01.xsd
- Currency
- GBP
- Source identifier
- Prod224_2166_08773116_20231231
- Source archive
- Accounts_Monthly_Data-May2024.zip
Accounts to 2022-12-31
IXBRL · 350 source facts · 37 selected values
Not assessedlegacy record
Accounts to 2022-12-31
IXBRL · 350 source facts · 37 selected values
Not assessed
legacy record
- Reporting period
- 2022-01-01 to 2022-12-31
- Extraction status
- Legacy / not assessed
- Numeric facts
- 229
- Documents processed
- Not recorded
- XBRL standards validation
- Not assessed
- Filing-profile validation
- Not assessed
- Parser
- Legacy parser
- Taxonomy
- FRS-102-2021-01-01.xsd
- Currency
- GBP
- Source identifier
- Prod224_0016_08773116_20221231
- Source archive
- Accounts_Monthly_Data-June2023.zip
Registered details
08773116- Status
- Active
- Type
- Private Limited Company
- Incorporated
- 2013-11-13
- Jurisdiction
- —
- Registered office
- MAGDALEN CENTRE, THE OXFORD SCIENCE PARK, OXFORD, OX4 4GA, UNITED KINGDOM
Classification
1 SIC codes23112
Capital & company events
Reconstructed equity rounds and matched research funding.
Equity fundraising
0 SH01-derived roundsNo reconstructed allotment rounds.
Research and innovation
1 matched grants18F FACBC an innovative imaging agent for the diagnosis of prostate cancer: a Phase III evaluation in recurrent prostate cancerLeadInnovate UK · Collaborative R&D · 2015-04-01 – 2018-03-31 · with 7 other participants£500,000awarded
18F FACBC an innovative imaging agent for the diagnosis of prostate cancer: a Phase III evaluation in recurrent prostate cancerLead
Innovate UK · Collaborative R&D · 2015-04-01 – 2018-03-31 · with 7 other participants
£500,000
awarded
Blue Earth Diagnostics Limitedlead£500,000
Greater Glasgow Health Board£184,746
Royal Marsden NHS Foundation Trust£130,627
Leeds Teaching Hospitals NHS Trust£123,354
East & North Hertfordshire NHS Trust£106,226
Oxford University Hospitals NHS Foundation Trust£83,692